Advances from clinical trials in juvenile idiopathic arthritis.
Nat Rev Rheumatol
; 9(9): 557-63, 2013 09.
Article
in En
| MEDLINE
| ID: mdl-23838613
ABSTRACT
Treatments available to children with juvenile idiopathic arthritis (JIA) have improved dramatically in the past 15 years, largely because of the development of powerful new biologic treatments. However, the seeds of this development were sewed over 40 years ago with the formation of a group of paediatric rheumatologists who understood the necessity of performing clinical trials in children with JIA. From there, international paediatric rheumatology networks have grown, and are dedicated to and highly experienced in performing such clinical trials. Development of validated outcomes and methodologies has also been critical. The ability to perform these trials stems from legislation enabling the FDA and the European Medicines Agency to require studies to be performed in children before they can be licensed for use in children. Current efforts to enhance the understanding of treatment options for patients with JIA include the development of disease-specific rather than drug-specific consolidated registries, studies in personalized predictive medicine and the development of treatment protocols for regular clinical care of these patients.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Arthritis, Juvenile
/
Biological Therapy
/
Clinical Trials as Topic
/
Antirheumatic Agents
Type of study:
Guideline
/
Prognostic_studies
Limits:
Adolescent
/
Child
/
Child, preschool
/
Humans
Language:
En
Journal:
Nat Rev Rheumatol
Journal subject:
REUMATOLOGIA
Year:
2013
Document type:
Article
Affiliation country:
United States
Publication country:
EEUU
/
ESTADOS UNIDOS
/
ESTADOS UNIDOS DA AMERICA
/
EUA
/
UNITED STATES
/
UNITED STATES OF AMERICA
/
US
/
USA